SynCore Bio is selected to present the Phase I study data of new anti-cancer molecule SB01 at ASCO 2017
SynCore Bio is selected to present the Phase I [...]
2017 Sinphar Bio-Forum – Cardiovascular Disease Management
On January 13th of this year, Sinphar Group held [...]
SynCoreBio significance progress in the negotiations of cooperation strategy. Breakthrough the predominance and maximizing the value of technology platform!
SynCoreBio together with its strategic partner German company Medigene [...]